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i.org/1dual antiplatelet therapy (DAPT) in “real-world” patients with atrial ﬁbrillation (AF) un-
dergoing percutaneous coronary intervention (PCI) have not yet been fully evaluated. In the
Coronary REvascularization Demonstrating Outcome Study in Kyoto registry cohort-2, a
total of 1,057 patients with AF (8.3%) were identiﬁed among 12,716 patients undergoing ﬁrst
PCI. Cumulative 5-year incidence of stroke was higher in patients with AF than in no-AF
patients (12.8% vs 5.8%, p <0.0001). Although most patients with AF had CHADS2 score
‡2 (75.2%), only 506 patients (47.9%) received OAC with warfarin at hospital discharge.
Cumulative 5-year incidence of stroke in the OAC group was not different from that in the no-
OAC group (13.8% vs 11.8%, p [ 0.49). Time in therapeutic range (TTR) was only 52.6%
with an international normalized ratio of 1.6 to 2.6, and only 154 of 409 patients (37.7%) with
international normalized ratio data had TTR ‡65%. Cumulative 5-year incidence of stroke in
patients with TTR ‡65% was markedly lower than that in patients with TTR <65% (6.9% vs
15.1%, p[ 0.01). In a 4-month landmark analysis in the OAC group, there was a trend for
higher cumulative incidences of stroke and major bleeding in the on-DAPT (n[ 286) than in
the off-DAPT (n [ 173) groups (15.1% vs 6.7%, p [ 0.052 and 14.7% vs 8.7%, p [ 0.10,
respectively). In conclusion, OAC was underused and its intensity was mostly suboptimal in
real-world patients with AF undergoing PCI, which lead to inadequate stroke prevention.
Long-term DAPT in patients receiving OAC did not reduce stroke incidence.  2014 The
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Figure 1. Study ﬂowchart. CABG ¼ coronary artery bypass grafting; M ¼ months.
Arrhythmias and Conduction Disturbances/Antithrombotics in AF Patients Undergoing PCI 71It has been reported that 5% to 10% of patients under-
going percutaneous coronary intervention (PCI) have
concomitant atrial ﬁbrillation (AF).1 Most of those patients
have an indication for oral anticoagulation (OAC) to prevent
stroke or systemic thromboembolism and also for anti-
platelet therapy to prevent ischemic cardiac events, partic-
ularly stent thrombosis (ST). Drug-eluting stents (DES) has
become widely used, and dual antiplatelet therapy (DAPT)
with aspirin plus thienopyridine for 12 months is recom-
mended after DES implantation.1 Thus, patients with AF
undergoing PCI often have an indication for long-term use
of OAC plus DAPT, although a great concern about
bleeding complications has been raised for such a “triple”
antithrombotic therapy.2e7 However, the prevalence and
intensity as well as the safety and efﬁcacy of OAC in
combination with DAPT in “real-world” patients with AF
undergoing PCI have not yet been fully evaluated. For pa-
tients receiving triple therapy in the real-world clinicalpractice, OAC could be less intensive because of a concern
about bleeding complications. It is unknown, however,
whether the less-intensive OAC in patients receiving
concomitant DAPT is effective in preventing stroke. Also
unknown is the effect of DAPT on long-term cardiovascular
outcomes in patients receiving concomitant OAC. Conse-
quently, we investigated the practice pattern and outcome
regarding OAC and DAPT use in patients with AF in a large
observational PCI database in Japan with 4 to 7 years of
follow-up.
Methods
The Coronary REvascularization Demonstrating Out-
come Study in Kyoto (CREDO-Kyoto) registry cohort-2 is a
physician-initiated, nonecompany sponsored, multicenter
registry enrolling consecutive patients undergoing ﬁrst
coronary revascularization among 26 centers in Japan from
Figure 2. Cumulative incidence of stroke comparing (A) AF versus no-AF patients, (B) OAC versus no-OAC at hospital discharge in patients with AF, and
(C) TTR 65% versus TTR <65% in the OAC patients.
72 The American Journal of Cardiology (www.ajconline.org)January 2005 to December 2007. The relevant review
boards or ethics committees in all 26 participating centers
(Supplementary Appendix A) approved the research
protocol.
A total of 15,939 patients undergoing ﬁrst coronary
revascularization were enrolled in the registry. We excluded
99 patients who refused study participation, 2,782 who
underwent coronary artery bypass grafting, and 342 who
died during the index hospitalization. Thus, the present
study’s population consisted of 12,716 patients undergoing
ﬁrst PCI who were alive at hospital discharge (Figure 1).
Recommended antiplatelet regimen for PCI stenting was
aspirin (81 mg/day) indeﬁnitely and thienopyridine (200-
mg ticlopidine or 75-mg clopidogrel per day) for at least
3 months. Choices regarding duration of DAPT and
administration of warfarin in patients with AF were left to
the discretion of each attending physician. Persistent
discontinuation of the antithrombotic drugs was deﬁned as
withdrawal lasting for at least 2 months. Withdrawal of
DAPT was deﬁned as persistent discontinuation of either
aspirin or thienopyridine.
We deﬁned patients with AF as those with a preexisting
diagnosis of AF and those who developed new-onset AFduring their index hospitalization. The primary outcome
measure was stroke including both ischemic and hemor-
rhagic strokes. Stroke was deﬁned as an acute onset of a
focal neurologic deﬁcit of presumed vascular origin
requiring hospitalization with symptoms lasting >24 hours
or resulting in death. The types of strokes were distin-
guished by imaging studies to be either hemorrhagic or
ischemic. Cerebral bleeding that occurred secondary to
ischemic stroke was not regarded as hemorrhagic stroke.
The secondary outcome measures were all-cause death,
myocardial infarction (MI), ST, and major bleeding. ST was
deﬁned as Academic Research Consortium deﬁnite ST.8
Major bleeding was deﬁned as moderate or severe
bleeding by Global Utilization of Streptokinase and Tissue
Plasminogen Activator for Occluded Coronary Arteries
classiﬁcation.9
Demographic, angiographic, and procedural data were
collected from hospital charts or hospital databases ac-
cording to prespeciﬁed deﬁnitions by experienced clinical
research coordinators from the study management center
(Research Institute for Production Development, Kyoto,
Japan; Supplementary Appendix B). Follow-up data were
obtained from hospital charts or by contacting patients or
Table 1
Unadjusted and adjusted clinical outcomes during follow-up
Clinical Outcome No. of Events
(5-Year Cumulative Incidence)
p Value Unadjusted HR
(95% CI)
Adjusted HR
(95% CI)
p Value
(A) AF versus No-AF AF (n ¼ 1057) No-AF (n ¼ 11659)
Stroke* 134 (12.8%) 666 (5.8%) <0.0001 2.47 (2.05e2.97) 2.00 (1.65e2.43) <0.0001
Ischemic or unspeciﬁed† 113 (10.9%) 515 (4.4%) <0.0001 2.68 (2.19e3.29) 2.16 (1.74e2.67) <0.0001
Hemorrhagic 23 (2.4%) 164 (1.5%) 0.02 1.69 (1.09e2.61) 1.40 (0.89e2.21) 0.15
All-caused death 312 (27.6%) 1753 (13.9%) <0.0001 2.18 (1.93e2.46) 1.43 (1.26e1.62) <0.0001
Major bleeding 166 (16.7%) 1200 (10.2%) <0.0001 1.66 (1.41e1.95) 1.22 (1.03e1.44) 0.02
Myocardial infarction 61 (6.5%) 559 (4.7%) 0.0497 1.30 (1.00e1.70) 1.22 (0.93e1.61) 0.15
Stent thrombosisz 18 (1.7%) 185 (1.6%) 0.62 1.13 (0.70e1.83) 1.17 (0.71e1.93) 0.53
(B) OAC versus No-OAC OAC (n ¼ 506) No-OAC (n ¼ 551)
Stroke* 68 (13.8%) 66 (11.8%) 0.49 1.13 (0.80e1.58) 1.20 (0.83e1.73) 0.34
Ischemic 57 (11.5%) 56 (10.3%) 0.59 1.11 (0.77e1.60) 1.22 (0.82e1.83) 0.33
Hemorrhagic 13 (3.2%) 10 (1.6%) 0.42 1.41 (0.62e3.21) 2.68 (0.78e9.24) 0.12
Allecaused death 142 (25.5%) 170 (29.4%) 0.35 0.90 (0.72e1.12) 0.93 (0.72e1.19) 0.56
Major bleeding 74 (16.2%) 92 (17.1%) 0.29 0.85 (0.63e1.15) 0.81 (0.58e1.13) 0.21
Myocardial infarction 17 (4.5%) 44 (8.5%) 0.001 0.40 (0.23e0.71) 0.39 (0.21e0.74) 0.004
Stent thrombosisz 4 (1.0%) 14 (2.5%) 0.03 0.31 (0.10e0.93) 0.14 (0.03e0.82) 0.03
(C) TTR 65% versus <65% TTR 65% (n ¼ 154) TTR <65% (n ¼ 255)
Stroke* 11 (6.9%) 36 (15.1%) 0.01 0.44 (0.22e0.87) 0.37 (0.16e0.86) 0.02
Ischemic 8 (4.9%) 30 (12.6%) 0.01 0.38 (0.18e0.84) 0.30 (0.11e0.81) 0.02
Hemorrhagic 4 (3.1%) 7 (3.4%) 0.85 0.89 (0.26e3.02) —x —
All-caused death 31 (17.8%) 74 (25.9%) 0.02 0.62 (0.41e0.94) 0.86 (0.51e1.43) 0.56
Major bleeding 17 (10.4%) 44 (19.6%) 0.06 0.59 (0.34e1.04) 0.50 (0.25e1.01) 0.053
Myocardial infarction 4 (3.1%) 10 (5.0%) 0.41 0.62 (0.19e1.97) —x —
Stent thrombosisz 1 (0.9%) 3 (1.3%) 0.57 0.53 (0.06e5.09) —x —
AF ¼ atrial ﬁbrillation; CI ¼ conﬁdence interval; HR ¼ hazard ratio; OAC ¼ oral anticoagulation; TTR ¼ time in therapeutic range.
* The sum of the numbers of ischemic (or unspeciﬁed) and hemorrhagic stroke events is not necessarily equal to the number of overall stroke events because
of patients with multiple events.
† Only 8 out of 800 strokes (1.0%) were unspeciﬁed because of lack of imaging information, all of which were in no-AF patients.
z Academic Research Consortium deﬁnite.
x Not available because of small number of events.
Arrhythmias and Conduction Disturbances/Antithrombotics in AF Patients Undergoing PCI 73physicians in charge. All the primary and secondary end
points were adjudicated by the independent clinical events
committee (Supplementary Appendix C).
Data for international normalized ratio (INR) during
follow-up in patients with AF receiving OAC were collected
from the hospital charts of the centers where the index PCI
was performed. Time in therapeutic range (TTR) in the
OAC group was calculated by the Rosendaal method,10
according to a therapeutic INR range of 1.6 to 2.6, which
is recommended for elderly (70 years) patients in the
Japanese guidelines.11 Because the stroke event may affect
the intensity of subsequent OAC, TTR in patients with such
an event during follow-up was calculated only using INR
data before or at the time of the stroke.
Data are presented as values and percentages, mean value
 SD, or median with ﬁrst quartile to third quartile (Q1 to
Q3). Categorical variables were compared with the chi-
square test or the Fisher’s exact test. Continuous variables
were compared using the Student t test or Wilcoxon rank
sum test based on their distributions. Cumulative incidence
was estimated by the Kaplan-Meier method, and differences
were assessed with the log-rank test.
We used the Cox proportional hazards model to adjust
for the differences in baseline patient characteristics, pro-
cedural factors, medications, and center. The unadjusted and
adjusted risks for clinical events are expressed as hazardratios with their 95% conﬁdence intervals. The detailed
methods of the multivariate analyses are described in
Supplementary Methods.
The landmark analysis based on DAPT use at 4 months
after the index PCI was conducted as described previ-
ously.12 Eligible patients for the landmark analysis were
those who were alive and free from stroke, MI, ST, and
major bleeding at the 4-month landmark point. Taking
a 1-month window period, the 4-month landmark point was
selected because DAPT for at least 3 months had been
recommended after implantation of sirolimus-eluting stent,
which was the most commonly used DES in this study
population.
All analyses were conducted by 2 physicians (KG and
KN) and a statistician (TMo) with the use of SAS 9.2 and
JMP 7.0 (SAS Institute Inc., Cary, North Carolina). All the
statistical analyses were 2-tailed, and probability values
<0.05 were considered statistically signiﬁcant.
Results
Among the entire 12,716 study patients, 1,057 patients
(8.3%) had AF. Baseline characteristics of the entire study
population comparing patients with AF and no-AF patients
are listed in Supplementary Table 1. During the median
follow-up of 5.1 years (Q1 to Q3; 4.3 to 5.9), a total of 2,065
Table 2
Baseline characteristics of AF patients comparing those with and without OAC at hospital discharge
Characteristic AF Patients
(n ¼ 1057)
OAC Group
(n ¼ 506)
No-OAC Group
(n ¼ 551)
p Value
Age (years) 72.5  9.3 72.0  8.8 73.0  9.7 0.04
Age 75 years 477 (45.1%) 212 (41.9%) 265 (48.1%) 0.04
Male 752 (71.1%) 383 (75.7%) 369 (67.0%) 0.002
AF type
Paroxysmal 652 (61.7%) 247 (48.8%) 405 (73.5%) <0.0001
Persistent/permanent 302 (28.6%) 207 (40.9%) 95 (17.2%)
Unknown 103 (9.7%) 52 (10.3%) 51 (9.3%)
Body mass index <25.0 kg/m2 766 (72.5%) 356 (70.4%) 410 (74.4%) 0.14
Acute myocardial infarction 392 (37.1%) 168 (33.2%) 224 (40.7%) 0.01
Hypertension 902 (85.3%) 435 (86.0%) 467 (84.8%) 0.58
Diabetes mellitus 362 (34.2%) 177 (35.0%) 185 (33.6%) 0.63
On insulin therapy 60 (5.7%) 25 (4.9%) 35 (6.4%) 0.32
Current smoker 237 (22.4%) 118 (23.3%) 119 (21.6%) 0.50
Heart failure 417 (39.5%) 201 (39.7%) 216 (39.2%) 0.86
Shock at presentation 98 (9.3%) 39 (7.7%) 59 (10.7%) 0.09
Multivessel coronary artery disease 529 (50.0%) 238 (47.0%) 291 (52.8%) 0.06
Ejection fraction 55.4  14.1 54.4  14.4 56.4  13.8 0.04
Mitral regurgitation grade 3/4 109 (10.3%) 53 (13.8%) 56 (15.2%) 0.59
Prior myocardial infarction 128 (12.1%) 62 (12.3%) 66 (12.0%) 0.89
Prior stroke 196 (18.5%) 96 (19.0%) 100 (18.2%) 0.73
Prior intracranial bleeding 27 (2.6%) 7 (1.4%) 20 (3.6%) 0.02
Peripheral vascular disease 87 (8.2%) 53 (10.5%) 34 (6.2%) 0.01
eGFR <30, not on dialysis 59 (5.6%) 28 (5.5%) 31 (5.6%) 0.95
Dialysis 48 (4.5%) 19 (3.8%) 29 (5.3%) 0.24
Anemia (Hb <11.0 g/dl) 153 (14.5%) 56 (11.1%) 97 (17.6%) 0.002
Platelet <100  109/L3 30 (2.8%) 13 (2.6%) 17 (3.1%) 0.61
Chronic obstructive pulmonary disease 43 (4.1%) 20 (4.0%) 23 (4.2%) 0.86
Liver cirrhosis 30 (2.8%) 17 (3.4%) 13 (2.4%) 0.33
Malignancy 108 (10.2%) 47 (9.3%) 61 (11.1%) 0.34
CHADS2 score 2.4  1.3 2.4  1.2 2.4  1.3 0.85
CHADS2 score 2 795 (75.2%) 389 (76.9%) 406 (73.7%) 0.23
CHA2DS2-VASc score 4.5  1.5 4.5  1.5 4.6  1.6 0.29
Stent use 959 (90.7%) 447 (88.3%) 512 (92.9%) 0.01
DES use 506 (47.9%) 264 (52.2%) 242 (43.9%) 0.007
Aspirin 1037 (98.1%) 495 (97.8%) 542 (98.4%) 0.52
Thienopyridine 1005 (95.1%) 473 (93.5%) 532 (96.6%) 0.02
DAPT 989 (93.6%) 465 (91.9%) 524 (95.1%) 0.03
Warfarin 506 (47.9%) 506 (100%) 0 (0%) —
Statins 430 (40.7%) 210 (41.5%) 220 (39.9%) 0.60
Beta-blockers 403 (38.1%) 221 (43.7%) 182 (33.0%) 0.0004
ACE-I/ARB 646 (61.1%) 328 (64.8%) 318 (57.7%) 0.02
Proton pump inhibitors 310 (29.3%) 132 (26.1%) 178 (32.3%) 0.03
ACE-I ¼ angiotensin converting enzyme inhibitor; AF ¼ atrial ﬁbrillation; ARB ¼ angiotensin receptor blocker; DAPT ¼ dual antiplatelet therapy;
DES ¼ drug-eluting stent; eGFR ¼ estimated glomerular ﬁltration rate; OAC ¼ oral anticoagulation.
74 The American Journal of Cardiology (www.ajconline.org)patients died and 800 patients had strokes. Cumulative 5-
year incidence of stroke was signiﬁcantly higher in pa-
tients with AF than in no-AF patients (12.8% and 5.8%, p
<0.0001; Figure 2). After adjusting for confounders, the
excess risk of stroke for patients with AF relative to no-AF
patients remained signiﬁcant (Table 1).
Among 1,057 patients with AF, although a large number
of patients had a CHADS2 score of 2, only 506 patients
(47.9%) received OAC with warfarin (Table 2).
Patients receiving OAC at hospital discharge compared
with no-OAC patients had greater prevalence of persistent or
permanent AF, although the distributions of the CHADS2
score were similar between the 2 groups (Table 2 and
Supplementary Figure 1). The vast majority of OAC patientsreceived concomitant DAPT, even though DAPT was less
prevalent in patients receiving OAC than in no-OAC patients.
After 5 years, OAC was discontinued in 22.7% of pa-
tients in the OAC group, whereas OAC was started in 31.6%
of patients in the no-OAC group (Supplementary Figure 2).
Cumulative 5-year incidence of stroke was high and not
signiﬁcantly different between the OAC and no-OAC
groups (13.8% and 11.8%, p ¼ 0.49; Figure 2). Even after
adjustment of baseline differences, the effect of OAC on
stroke remained insigniﬁcant. Cumulative incidence of
major bleeding also showed no difference between the OAC
and no-OAC groups. Cumulative incidence of MI and ST
was signiﬁcantly lower in the OAC group than in the no-
OAC group (Table 1).
Figure 3. (A) Percentages of time spent below, within, and above the
therapeutic INR range in the OAC group. (B) Distributions of TTR in the
OAC group. (C) Latest INR value within 30 days before or at the time of
stroke in the OAC group.
Figure 4. Cumulative incidences of (A) stroke and (B) major bleeding in the
patients receiving OAC based on DAPT use at the 4-month landmark point.
LP ¼ landmark point; M ¼ months.
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(80.8%) in the OAC group, excluding 66 patients with no
INR data and 31 patients with only 1 set of INR data
(Figure 1). The median of available INR data per patientwas 17 (Q1 to Q3; 6 to 35), and median interval of INR
measurements was 49 days (Q1 to Q3; 30 to 90).
With a therapeutic INR range of 2.0 to 3.0, the average
TTR was only 24.2%, and most of the time (72.4%) was
spent below the therapeutic INR range. Only 22 patients
(5.4%) had TTR 65%. Even with a therapeutic INR range
of 1.6 to 2.6, the average TTR was 52.6%, and only 154
patients (37.7%) had TTR 65% (Figure 3).
Baseline characteristics including the CHADS2 score
were similar between the 2 groups of patients with TTR
65% (n ¼ 154) and TTR <65% (n ¼ 255) with the INR
range of 1.6 to 2.6 (Supplementary Table 2). Cumulative 5-
year incidence of stroke was signiﬁcantly lower in patients
with TTR 65% than in those with TTR <65% (6.9% and
15.1%, p ¼ 0.01; Figure 2). After adjusting for confounders,
TTR 65% remained to be signiﬁcantly associated with
lower risk of stroke (Table 1). Of 68 patients in the OAC
group who had stroke during follow-up, INR data within
30 days before or at the time of the stroke were available in
27 patients. Ischemic stroke occurred mostly in patients with
latest INR values of <1.6 (Figure 3).
During follow-up, DAPT was maintained in more pa-
tients in the OAC group than in the no-OAC group
76 The American Journal of Cardiology (www.ajconline.org)(Supplementary Figure 3). At 4 months, DAPT was main-
tained in 286 of 459 OAC patients (62.3%) eligible for the
landmark analysis. More patients in the on-DAPT group at 4
months had multivessel coronary artery disease and DES
use compared with the off-DAPT group (Supplementary
Table 3). The average TTR was signiﬁcantly lower in on-
DAPT than in off-DAPT patients (49.2% vs 59.1%, p ¼
0.002). Cumulative incidences of stroke and major bleeding
including hemorrhagic stroke tended to be greater in on-
DAPT than in off-DAPT patients (Figure 4). There were
no differences in the cumulative incidences of MI and ST
regardless of DAPT use at 4 months (Supplementary
Table 4).
Discussion
The main ﬁndings of the present study were as follows:
(1) in real-world patients with AF undergoing PCI, OAC
was underused, and its intensity was mostly suboptimal; (2)
OAC at hospital discharge was not associated with lower
stroke incidence presumably because of its low intensity
overall; (3) optimal compared with suboptimal OAC was
associated with markedly lower stroke incidence; and (4)
prolonged DAPT in addition to OAC did not reduce stroke
risk.
To date, there have been no randomized controlled trials
assessing the efﬁcacy and safety of OAC in patients with AF
receiving DAPT. The present study evaluated the real-world
practice pattern and long-term outcomes of anticoagulant
and antiplatelet therapy in >1,000 patients with AF under-
going PCI from a large observational database. The median
follow-up duration of 5.1 years was the longest among the
studies, and detailed antiplatelet therapy and OAC data
during follow-up were available, including INR values.
Although Lamberts et al5,6 recently reported results of a
nationwide cohort study in Denmark including approxi-
mately 12,000 patients with AF hospitalized with MI or for
PCI, the duration of follow-up was short (mean 288 days),
and detailed data regarding antiplatelet therapy and OAC
during follow-up were not available. The present study
showed that optimization of OAC is crucial for stroke pre-
vention in patients with AF even in the setting of post-PCI
with mandatory DAPT. In contrast, no clinical beneﬁt but
possible harm of prolonged DAPT beyond 4 months after
PCI was suggested.
Despite 3/4 of patients with AF having a CHADS2 score
of2, OAC was used only in 47.9% of patients in this study,
which is consistent with previous reports. Among previous
observational studies that included patients undergoing PCI
with an indication for OAC, the prevalence of OAC ranged
from 9% to 85% with an average of 51%.2,4e7,13 Thus, in
real-world patients with AF undergoing PCI, OAC is un-
derused presumably because of physicians’ concern about
bleeding complications. Most previous studies, indeed,
showed high hemorrhagic risk for triple therapy, 2e7 up to 6
times higher than no-triple therapy.2
OAC with dose-adjusted warfarin compared with either
placebo, aspirin, or DAPT was associated with marked risk
reduction for stroke in randomized controlled trials.14,15
Furthermore, several previous observational studies in the
PCI setting also showed better cardiovascular outcomes,despite excess in bleeding events, in patients receiving OAC
than in patients not receiving OAC.4e7,16 In the present
study, however, OAC at hospital discharge was not asso-
ciated with lower risk for stroke. The main reason for the
lack of efﬁcacy of OAC in preventing stroke could be the
low intensity of OAC observed in the present study. Only
37.7% of patients had TTR 65% even when the thera-
peutic INR range was set at lower range of 1.6 to 2.6. Pa-
tients with TTR 65% actually had a markedly lower risk
for stroke than patients with TTR <65%.
There is insufﬁcient data regarding the intensity of OAC
in patients with AF undergoing PCI. Only 2 observational
studies have addressed this issue to date, although TTR data
were not available. Rossini et al prospectively evaluated 102
patients, targeting INR in the range of 2.0 to 2.5, and INR at
30 days after PCI was within the target range in 81 patients
(79.4%). Patients with an INR above the target range were
associated with extremely high bleeding events compared to
those with an INR within the target range (33% vs 4.9%, p
<0.0001).3 Also, Gao et al prospectively evaluated 267
patients with AF receiving OAC, and 1,457 of 2,023
measured INR values (72%) were within the target range of
1.8 to 2.5. INR values at the time of major bleeding were
above the target range in all cases.4 Presumably because of
the prospective design, the INR control in these 2 studies
was excellent. However, in real-world patients with AF
undergoing PCI, OAC may be less intensive than that
observed in prospective studies or randomized controlled
trials. In the non-PCI AF population, TTR in the retro-
spective studies range from 29% to 75% with an average of
53% in contrast to that in the randomized controlled trials,
ranging from 44% to 73% with an average of 67%.17 In the
real-world PCI population with mandatory DAPT at hospital
discharge, the intensity of OAC could be further shifting to
lower INR control because of physicians’ concern about
bleeding complications, as shown in our study. Conversely,
however, the present study strongly suggests that the opti-
mization of OAC would be crucial for stroke prevention in
patients with AF undergoing PCI.
In the present study, DAPT was maintained beyond 4
months in a signiﬁcant proportion of patients with AF
receiving OAC. In the 4-month landmark analysis, OAC
was less intensive in on-DAPT than in off-DAPT patients,
leading to a trend toward greater incidence of stroke in on-
DAPT patients. Also, on-DAPT patients tended to have
higher risk of major bleeding compared with off-DAPT
patients. Furthermore, there was no difference in the risk
of MI or ST between the 2 groups. Several recent ran-
domized controlled trials and observational studies enrolling
patients mostly without AF suggested that prolonged DAPT
after PCI, compared with short-term DAPT, did not
demonstrate better cardiovascular outcomes, including ST,
but was associated with excess bleeding events.18e20
Considering the increased risk of major bleeding in the
setting of triple therapy, duration of DAPT should be as
short as possible. To reduce stroke risk, we should focus
more on optimizing OAC rather than prolonging DAPT.
The What is the Optimal antiplatElet and anticoagulant
therapy in patients with oral anticoagulation and coronary
StenTing study demonstrated that triple therapy (OAC plus
DAPT) compared with double therapy (OAC plus
Arrhythmias and Conduction Disturbances/Antithrombotics in AF Patients Undergoing PCI 77clopidogrel) was associated with signiﬁcantly higher rates of
bleeding events without any improvement of cardiovascular
outcomes.21 Double therapy with OAC plus a thienopyr-
idine may be an attractive alternative to triple therapy. The
recent report by Lamberts et al6 also supports this thera-
peutic concept.
There are several important limitations in this study.
First, because of the observational study design, we could
not deny the inﬂuence of selection bias and unmeasured
confounders regarding the effect of OAC on stroke reduc-
tion. Second, stroke was not adjudicated by neurologists on
routine examination. Third, we did not have INR data for all
patients with OAC, and the number and interval of INR
measurements varied widely among patients. Fourth, there
was substantial crossover between the OAC and no-OAC
groups during follow-up, although the degree of crossover
was relatively low compared with recent OAC studies.15,22
Fifth, there may be some difference in the intensity of
OAC for patients with AF in a real clinical practice between
Asian and Western countries. Asians have been reported to
be associated with 4 times higher risk of intracranial hem-
orrhage than Caucasians receiving OAC with warfarin.23
Also, elderly Japanese patients are known to have high
risk of major bleeding at the INR level of >2.6,24,25 which
lead to the recommendation of low intensity INR control
(1.6 to 2.6) for elderly patients in the Japanese guidelines.11
Indeed, Asian physicians prefer low intensity INR control
regardless of patient’s age even in the setting of randomized
controlled trials.26,27 Finally, TTR cut-off level of 65% ac-
cording to the INR range of 1.6 to 2.6 was not prespeciﬁed.
However, the results were consistent even when the TTR
cut-off level was set at either 60% or 70% (Supplementary
Figure 4).Disclosures
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found, in the online version at http://dx.doi.org/10.1016/j.
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